Journal article
Glutamate Receptor Antagonists as Fast-Acting Therapeutic Alternatives for the Treatment of Depression: Ketamine and Other Compounds
Annual review of pharmacology and toxicology, Vol.54(1), pp.119-139
2014
DOI: 10.1146/annurev-pharmtox-011613-135950
PMCID: PMC4089991
PMID: 24392693
Abstract
The
N
-methyl-
d
-aspartate (NMDA) receptor antagonist ketamine has rapid and potent antidepressant effects in treatment-resistant major depressive disorder and bipolar depression. These effects are in direct contrast to the more modest effects seen after weeks of treatment with classic monoaminergic antidepressants. Numerous open-label and case studies similarly validate ketamine’s antidepressant properties. These clinical findings have been reverse-translated into preclinical models in an effort to elucidate ketamine’s antidepressant mechanism of action, and three important targets have been identified: mammalian target of rapamycin (mTOR), eukaryotic elongation factor 2 (eEF2), and glycogen synthase kinase-3 (GSK-3). Current clinical and preclinical research is focused on (
a
) prolonging/maintaining ketamine’s antidepressant effects, (
b
) developing more selective NMDA receptor antagonists free of ketamine’s adverse effects, and (
c
) identifying predictor, mediator/moderator, and treatment response biomarkers of ketamine’s antidepressant effects.
Details
- Title: Subtitle
- Glutamate Receptor Antagonists as Fast-Acting Therapeutic Alternatives for the Treatment of Depression: Ketamine and Other Compounds
- Creators
- Mark J Niciu - Icahn School of Medicine at Mount Sinai, New York, NY 10029Ioline D Henter - Icahn School of Medicine at Mount Sinai, New York, NY 10029David A Luckenbaugh - Icahn School of Medicine at Mount Sinai, New York, NY 10029Carlos A Zarate - Icahn School of Medicine at Mount Sinai, New York, NY 10029Dennis S Charney - Icahn School of Medicine at Mount Sinai, New York, NY 10029
- Resource Type
- Journal article
- Publication Details
- Annual review of pharmacology and toxicology, Vol.54(1), pp.119-139
- DOI
- 10.1146/annurev-pharmtox-011613-135950
- PMID
- 24392693
- PMCID
- PMC4089991
- NLM abbreviation
- Annu Rev Pharmacol Toxicol
- ISSN
- 0362-1642
- eISSN
- 1545-4304
- Publisher
- Annual Reviews
- Language
- English
- Date published
- 2014
- Academic Unit
- Psychiatry; Iowa Neuroscience Institute
- Record Identifier
- 9984003957102771
Metrics
19 Record Views